Overview
Toripalimab is under investigation in clinical trial NCT03919383 (Phase II of Lenvatinib Plus Toripalimab for Advanced HCC).
Indication
⑴用于治疗既往标准治疗失败后的局部进展或转移性黑色素瘤。⑵用于治疗既往接受过二线及以上系统治疗失败的复发/转移性鼻咽癌（NPC）。⑶用于治疗既往接受过治疗的局部进展或转移性尿路上皮癌（UC）。⑷用于食管鳞癌一线治疗。
Associated Conditions
No associated conditions information available.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2025/08/25 | Not Applicable | Not yet recruiting | |||
2025/08/22 | Not Applicable | Not yet recruiting | Affiliated Hospital of Guangdong Medical University | ||
2025/08/08 | Not Applicable | Not yet recruiting | |||
2025/08/01 | Not Applicable | Not yet recruiting | Shanghai Pulmonary Hospital, Shanghai, China | ||
2025/08/01 | Not Applicable | Not yet recruiting | |||
2025/07/30 | Not Applicable | Recruiting | |||
2025/06/27 | Not Applicable | Not yet recruiting | |||
2025/06/26 | Phase 2 | Recruiting | Wen-zhao ZHONG | ||
2025/06/04 | Phase 1 | Recruiting | Sichuan University | ||
2025/05/23 | Phase 2 | Not yet recruiting | Sun Yat-sen University |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| Coherus BioSciences, Inc. | 70114-340 | INTRAVENOUS | 240 mg in 6 mL | 10/23/2023 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
Authorised | 9/19/2024 |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| LOQTORZI CONCENTRATE FOR SOLUTION FOR INFUSION 240MG/6ML | SIN17212P | INFUSION, SOLUTION CONCENTRATE | 240mg/6mL | 3/26/2025 |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| LOQTORZI CONCENTRATE FOR SOLUTION FOR INFUSION 240MG/6ML | N/A | N/A | N/A | 10/11/2024 |
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| ZYTORVI toripalimab 240 mg/ 6 mL concentrated injection vial | 426950 | Medicine | A | 1/21/2025 |
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
|---|---|---|---|---|---|
| No Health Canada approvals found for this drug. | |||||
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
|---|---|---|---|---|---|
| No CIMA AEMPS (Spain) approvals found for this drug. | |||||
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Philippines FDA approvals found for this drug. | |||||
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Saudi SFDA approvals found for this drug. | |||||
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Malaysia NPRA approvals found for this drug. | |||||
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
|---|---|---|---|---|---|
| No UK EMC drug information found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.